KalVista Pharmaceuticals (NASDAQ:KALV) Rating Increased to Strong-Buy at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV) to a strong-buy rating in a research report report published on Monday, Zacks.com reports. Cantor Fitzgerald also issued estimates for KalVista Pharmaceuticals’ FY2025 earnings at ($3.44) EPS.

Other equities research analysts also recently issued reports about the company. HC Wainwright reaffirmed a buy rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Monday, July 15th. Needham & Company LLC reduced their price objective on shares of KalVista Pharmaceuticals from $35.00 to $32.00 and set a buy rating for the company in a research note on Friday, July 12th.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $13.00 on Monday. KalVista Pharmaceuticals has a 12 month low of $7.21 and a 12 month high of $16.88. The firm has a market capitalization of $548.44 million, a PE ratio of -3.82 and a beta of 0.91. The company’s 50 day simple moving average is $13.02 and its 200 day simple moving average is $12.50.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, July 11th. The specialty pharmaceutical company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.29). Sell-side analysts anticipate that KalVista Pharmaceuticals will post -3.38 earnings per share for the current fiscal year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 14,215 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $12.01, for a total value of $170,722.15. Following the completion of the sale, the chief executive officer now directly owns 242,527 shares of the company’s stock, valued at $2,912,749.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Benjamin L. Palleiko sold 7,465 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $11.53, for a total value of $86,071.45. Following the transaction, the chief executive officer now directly owns 224,547 shares of the company’s stock, valued at approximately $2,589,026.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Benjamin L. Palleiko sold 14,215 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $12.01, for a total value of $170,722.15. Following the completion of the sale, the chief executive officer now owns 242,527 shares of the company’s stock, valued at $2,912,749.27. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,917 shares of company stock valued at $368,563. 12.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of KALV. Susquehanna Fundamental Investments LLC grew its holdings in KalVista Pharmaceuticals by 323.5% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 68,526 shares of the specialty pharmaceutical company’s stock valued at $807,000 after buying an additional 52,347 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after acquiring an additional 3,314 shares during the period. Great Point Partners LLC acquired a new stake in shares of KalVista Pharmaceuticals in the second quarter worth $15,768,000. Evoke Wealth LLC bought a new position in KalVista Pharmaceuticals during the second quarter worth $181,000. Finally, Nicholas Investment Partners LP raised its stake in KalVista Pharmaceuticals by 0.9% during the 2nd quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock valued at $2,172,000 after purchasing an additional 1,714 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.